NORTH AMERICA OPIOIDS DRUGS MARKET FORECAST 2019-2028

NORTH AMERICA OPIOIDS DRUGS MARKET FORECAST 2019-2028

  • May 2020 •
  • 121 pages •
  • Report ID: 5893081 •
  • Format: PDF
KEY FINDINGS
The North America opioids drugs market is anticipated to register a CAGR of 2.25% over the estimated period of 2019-2028. The increasing pharmaceutical expenditure, the growing prevalence, and a patient pool of opioid addiction and dependence, are some of the significant factors propelling market growth in the region.
MARKET FINDINGS
The North America opioids drugs market is further researched by dividing the region into the United States and Canada. Canada spends 11.5% of its GDP on healthcare, according to the OECD 2018 report. In Canada, the implementation of government policies, rising occurrence of opioids abuse, and strict regulatory measures for opioids drugs sale are hindering market growth in the region. The decreasing prescription volume of strong opioids is the primary factor affecting the growth of the market in the country. In 2017, about 4000 Canadians died from an opioid-related overdose. Moreover, from 2012-2016, the total number of daily doses for opioids reduced a little less than 5% all over Canada, but there is a steady increase in prescription opioids by 7%. Both the United States and Canada have taken stringent measures to control the epidemic nature of opioids usage and created guidelines for doctors, aimed at reducing opioid prescriptions. As per the PHN, opioid prescriptions lessened in 2017, and the overall quantity of distributed opioids decreased by 10.1% from 2016-2017. British Columbia, Canada’s Pacific province was hit by coronavirus when already battling an opioid epidemic. In March, the Canadian government urged the provinces to lower restrictions on prescription medications.

COMPETITIVE INSIGHTS
Biodelivery Sciences International, Inc, Egalet Corp, Acura Pharmaceuticals, Inc, Johnson & Johnson, Pfizer Inc, etc. are some of the prominent companies functioning in the market.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. ACURA PHARMACEUTICALS INC
2. ALLERGAN PLC
3. BIODELIVERY SCIENCES INTERNATIONAL INC
4. CIPHER PHARMACEUTICALS INC
5. COLLEGIUM PHARMACEUTICAL INC
6. DAIICHI SANKYO INC
7. EGALET CORP
8. HIKMA PHARMACEUTICALS PLC
9. INDIVIOR INC
10. JANSSEN PHARMACEUTICALS INC
11. JOHNSON & JOHNSON
12. LANNETT CO. INC
13. LUPIN LTD
14. MYLAN NV
15. PFIZER INC
16. PURDUE PHARMA LP
17. SANOFI-AVENTIS S.A
18. SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
19. TEVA PHARMACEUTICAL INDUSTRIES LTD